Bayer today announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer. As announced previously, Bayer now ...

Bayer is handing over up to $2.45bn to acquire Perfuse Therapeutics – marking the company’s first bid to enhance its legacy in the ophthalmology market since the patent expiry of its best-selling eye ...

The German pharmaceutical-and-agricultural group said the acquisition would complement its drug pipeline and leverage its ophthalmology footprint.

Bayer has acquired Perfuse Therapeutics, including the full rights to the PER-001 intravitreal implant, which is in ...

Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the ...

Bayer is paying $300 million to buy Perfuse Therapeutics, a clinical-stage biotech that offers a new growth opportunity in ophthalmology as the pharmaceutical company’s top eye product weathers ...

Bayer has agreed terms for its first biopharma acquisition in years, paying $300 million upfront for privately-held US biotech Perfuse Therapeutic and its novel drug implant for eye diseases. The deal ...

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and ...